Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $142.80 | Total: $714.00 |
| 1 | 10 | $120.96 | Total: $1,209.60 |
| 1 | 25 | $102.48 | Total: $2,562.00 |
| 1 | 50 | $87.36 | Total: $4,368.00 |
| 1 | 100 | $75.60 | Total: $7,560.00 |
Overview
MI-3454 is an orally active, selective and potent inhibitor of Menin-MLL1 interaction that inhibits the proliferation and induces differentiation of acute leukemia cells with MLL1 translocation or NPM1 mutation.MI-3454 induces complete remission or regression of leukemia in a mouse model of leukemia with MLL1 rearrangement or NPM1 mutation through the down-regulation of key genes involved in leukemogenesis. complete remission or remission.
Chemical Properties
| Molecular Formula | C32H35F3N8OS |
| Molecular Weight | 636.73 |
| CAS Numbers | 2134169-43-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CNc1nc(NC2CCN(Cc3ccc4n(CC56CC(C5)(C6)NC=O)c(cc4c3C)C#N)CC2)c2cc(CC(F)(F)F)sc2n1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Szymon Klossowski, et al. Menin Inhibitor MI-3454 Induces Remission in MLL1 -rearranged and NPM1 -mutated Models of Leukemia. J Clin Invest. 2020 Feb 3;130[2] 981-997.